Please use this identifier to cite or link to this item: doi:10.22028/D291-43319
Title: High Target Homology Does Not Guarantee Inhibition: Aminothiazoles Emerge as Inhibitors of Plasmodium falciparum
Author(s): Johannsen, Sandra
Gierse, Robin M.
Krüger, Arne
Edwards, Rachel L.
Nanna, Vittoria
Fontana, Anna
Zhu, Di
Masini, Tiziana
de Carvalho, Lais Pessanha
Poizat, Mael
Kieftenbelt, Bart
Hodge, Dana M.
Alvarez, Sophie
Bunt, Daan
Lacour, Antoine
Shams, Atanaz
Meissner, Kamila Anna
de Souza, Edmarcia Elisa
Dröge, Melloney
van Vliet, Bernard
den Hartog, Jack
Hutter, Michael C.
Held, Jana
Odom John, Audrey R.
Wrenger, Carsten
Hirsch, Anna
Language: English
Title: ACS infectious diseases
Volume: 10
Issue: 3
Publisher/Platform: ACS
Year of Publication: 2024
DDC notations: 500 Science
Publikation type: Journal Article
Abstract: In this study, we identified three novel compound classes with potent activity against Plasmodium falciparum, the most dangerous human malarial parasite. Resistance of this pathogen to known drugs is increasing, and compounds with different modes of action are urgently needed. One promising drug target is the enzyme 1-deoxy-d-xylulose-5-phosphate synthase (DXPS) of the methylerythritol 4-phosphate (MEP) pathway for which we have previously identified three active compound classes against Mycobacterium tuberculosis. The close structural similarities of the active sites of the DXPS enzymes of P. falciparum and M. tuberculosis prompted investigation of their antiparasitic action, all classes display good cell-based activity. Through structure-activity relationship studies, we increased their antimalarial potency and two classes also show good metabolic stability and low toxicity against human liver cells. The most active compound 1 inhibits the growth of blood-stage P. falciparum with an IC50 of 600 nM. The results from three different methods for target validation of compound 1 suggest no engagement of DXPS. All inhibitor classes are active against chloroquine-resistant strains, confirming a new mode of action that has to be further investigated.
DOI of the first publication: 10.1021/acsinfecdis.3c00670
URL of the first publication: https://pubs.acs.org/doi/10.1021/acsinfecdis.3c00670
Link to this record: urn:nbn:de:bsz:291--ds-433195
hdl:20.500.11880/38856
http://dx.doi.org/10.22028/D291-43319
ISSN: 2373-8227
Date of registration: 30-Oct-2024
Faculty: NT - Naturwissenschaftlich- Technische Fakultät
Department: NT - Pharmazie
Professorship: NT - Prof. Dr. Anna Hirsch
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes



This item is licensed under a Creative Commons License Creative Commons